Venetoclax is a BCL-2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), among other approved uses. It is available as tablets and kits for oral use. MedsAcross supplies Venetoclax for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Source: US FDA prescribing information
Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL and AML cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.
Source: US FDA prescribing information
See Full Prescribing Information for recommended VENCLEXTA dosages. Take VENCLEXTA tablets orally once daily with a meal and water. Provide prophylaxis for tumor lysis syndrome.
Source: US FDA prescribing information
Concomitant use of VENCLEXTA with strong CYP3A inhibitors at initiation and during the ramp-up phase is contraindicated in patients with CLL/SLL due to the potential for increased risk of tumor lysis syndrome. Concomitant use with strong CYP3A inhibitors at initiation and during ramp-up phase in patients with CLL/SLL is contraindicated.
Source: US FDA prescribing information
Tumor Lysis Syndrome (TLS): Anticipate TLS, assess risk in all patients. Premedicate with anti-hyperuricemics and ensure adequate hydration. Employ more intensive measures (intravenous hydration, frequent monitoring, hospitalization) as overall risk increases. Neutropenia: Monitor blood counts. Interrupt dosing and resume at same or reduced dose. Consider supportive care measures. Infections: Monitor for signs and symptoms of infection and treat promptly. Withhold for Grade 3 and 4 infection until resolution and resume at same or reduced dose. Immunization: Do not administer live attenuated vaccines prior to, during, or after treatment with VENCLEXTA until B-cell recovery. Embryo-Fetal Toxicity: May cause embryo-fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Tumor Lysis Syndrome Neutropenia Infections In CLL/SLL, the most common adverse reactions (≥20%) for VENCLEXTA when given in combination with obinutuzumab or rituximab or as monotherapy are neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, and edema. In CLL/SLL, the most common adverse reactions (≥20%) for VENCLEXTA when given in combination with acalabrutinib are neutropenia, headache, diarrhea, musculoskeletal pain, and COVID-19.
Source: US FDA prescribing information
Strong or moderate CYP3A inhibitors or P-gp inhibitors: Adjust dosage of VENCLEXTA. Strong or moderate CYP3A inducers: Avoid co-administration. P-gp substrates: Take at least 6 hours before VENCLEXTA.
Source: US FDA prescribing information
Store in original container at or below 86°F (30°C). Dispense to patient in original container to protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Venetoclax, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Venclexta 100 mg tabletOral | AbbVie | US FDA | Available on request |
| Venclexta 10 mg tabletOral | AbbVie | US FDA | Available on request |
| Venclexta 50 mg tabletOral | AbbVie | US FDA | Available on request |
| Venclexta kit | AbbVie | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Venetoclax in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Venetoclax and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Venetoclax, including Venclexta.
Yes. The US FDA first approved Venetoclax on 11 April 2016, according to Drugs@FDA.
Yes. Venetoclax has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Venetoclax is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Venetoclax is classified under ATC code L01XX52 (Venetoclax).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.